News Archive

WellDoc®, developers of the first FDA cleared mobile prescription therapy, BlueStarTM, announced today that it received funding from its first institutional investors, Merck Global Health Innovation Fund and Windham Venture Partners, as part of a $20M round of financing that now broadens its capitalization beyond its initial group of angel investors. For a limited time, WellDoc and its investors will also explore the possibility of adding co-investors that bring strategic value to the company.

“Our new investors share WellDoc’s vision of fundamentally changing how people manage their chronic diseases to improve outcomes and reduce costs,” said Ryan Sysko, co-founder and CEO of WellDoc. “This investment will help WellDoc launch and commercialize BlueStar, the world’s first Mobile Prescription Therapy for type 2 diabetes, on a nationwide basis.”

Johnson & Johnson Innovation has announced that it is expanding its global incubator presence through a novel collaboration with the Office of the Chief Scientist in Israel and other industry partners to establish a new biotechnology incubator near Israel’s Weizmann Science Park.

This is the latest in a series of recently announced collaborations to fuel entrepreneurship in the world’s scientific hotspots. In addition, Johnson & Johnson Innovation announced several new collaborations with academia and biotech that focus on multiple disease areas and consumer healthcare challenges.

AstraZeneca today announced that Granta Park-based MedImmune, its global biologics research and development arm, has entered into a cancer research collaboration and licensing agreement with Immunocore, an Oxford biotech company.

The approach will be to use the power of the body’s own immune system to find and kill diseased cells, avoiding damage to healthy cells.

Intrexon Corporation (NYSE: XON), a leader in synthetic biology, announced today that it has entered into a research and development collaboration with Johnson & Johnson Innovation and its affiliate Johnson & Johnson Consumer & Personal Products Worldwide, a division of Johnson & Johnson Consumer Companies, Inc., to advance new skin and hair care products.

“We look forward to advancing new skin and hair beauty products that have measurable impact for consumers,” said Randal J. Kirk, Chairman and Chief Executive Officer, Intrexon.  “By combining Intrexon’s synthetic biology approaches with the capabilities at Johnson & Johnson Innovation and Johnson & Johnson Consumer & Personal Products Worldwide, we believe that there are multiple areas for new product exploration.”

Neuralstem, Inc. (NYSE MKT: CUR) announced today that it has entered into agreements with leading institutional investors for a registered direct placement (the “Offering”) of 6,752,744 shares of common stock at a price of $2.91 per share, resulting in aggregate gross proceeds of approximately $19.65 million.

In addition, the Company will issue to each investor a warrant to purchase a number of shares of common stock equal to one-half of the number of shares purchased by the investor in the Offering. The warrants have an exercise price of $3.64 per share, and are exercisable from the issuance date, for a period of five years.

Elliott Sigal has opened the next chapter of his career. The former R&D chief at Bristol-Myers Squibb ($BMY), who helped squire a number of blockbuster programs through the clinic, is joining David Mott as a venture partner at New Enterprise Associates.

Bristol-Myers’ R&D group had its setbacks, particularly in 2012, but during Sigal’s tenure at the top of the research arm he guided an amazing 14 drugs to an approval, including Abilify, Erbitux and Onglyza. Those were all part of Bristol-Myers’ “string of pearls,” which earned the company a rep as one of the leaders in innovation in the field. Few other R&D chiefs–including a number who had much larger budgets to work with–even came close.

GlaxoSmithKline plc [LSE/NYSE: GSK ] announced today that the U.S. Food and Drug Administration (FDA) has approved Mekinist® (trametinib) for use in combination with Tafinlar® (dabrafenib) for the treatment of patients with unresectable melanoma (melanoma that cannot be removed by surgery) or metastatic melanoma (melanoma which has spread to other parts of the body) with BRAF V600E or V600K mutations. These mutations must be detected by an FDA-approved test.1 Tafinlar is not indicated for treatment of patients with wild-type BRAF melanoma.2

The approval of the combination is based on the demonstration of response rate and median duration of response in a Phase I/II study. Improvement in disease-related symptoms or overall survival has not been demonstrated for Mekinist in combination with Tafinlar.1 The combination was approved through the FDA’s Accelerated Approval programme and reviewed under a Priority Review designation.3 This accelerated approval is contingent on the results of the ongoing Phase III trial (referred to as MEK115306 or Combi-D), which is designed to evaluate the clinical benefit of the combination in this patient population.

The International CES expo in Las Vegas, which kicks off Tuesday, has long been the site of new technology announcements and gadget demonstrations. This year, about 55 Washington area companies plan to exhibit at the show, up slightly from last year’s 53.

The group represents one of the most diverse that the region has sent to Las Vegas, said Jeff Joseph, senior vice president for communications with the Consumer Electronics Association, which puts on the show.

The healthcare industry will continue to command the spotlight in 2014, and healthcare executive search consultants from Witt/Kieffer have some advice for making 2014 a stellar year on the work front, including a recommendation to broaden the role of the CIO.

The recommendations:

Prepare for unplanned CEO turnover – Paul Bohne, managing partner, says, “Technological advancements, physician alignment, market consolidation and government policy changes have all increased the complexities of how large, diverse healthcare organizations operate.” These mounting responsibilities have exacerbated the turnover issue.

New survey data result in an upward revision of the previously published 2011 U.S. research and development performance total and imply a sizable further expansion in 2012. These new data puts U.S. R&D expenditures at $428.2 billion in 2011,[2] an increase of $20.5 billion over the 2010 level ( table 1, figure 1 ). The preliminary estimate of the 2012 U.S. total for R&D is $452.6 billion.